166 related articles for article (PubMed ID: 15711125)
1. The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor-bearing mice.
Gupta S; Mathur R; Dwarakanath BS
Cancer Biol Ther; 2005 Jan; 4(1):87-94. PubMed ID: 15711125
[TBL] [Abstract][Full Text] [Related]
2. 2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.
Dwarakanath BS; Khaitan D; Ravindranath T
Cancer Biol Ther; 2004 Sep; 3(9):864-70. PubMed ID: 15254410
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization of murine Ehrlich ascites tumor by a combination of 2-deoxy-D-glucose and 6-aminonicotinamide.
Varshney R; Gupta S; Dwarakanath BS
Technol Cancer Res Treat; 2004 Dec; 3(6):659-63. PubMed ID: 15560724
[TBL] [Abstract][Full Text] [Related]
4. Hematoporphyrin derivatives potentiate the radiosensitizing effects of 2-deoxy-D-glucose in cancer cells.
Dwarakanath BS; Adhikari JS; Jain V
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):1125-33. PubMed ID: 10192364
[TBL] [Abstract][Full Text] [Related]
5. Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.
Singh S; Pandey S; Bhatt AN; Chaudhary R; Bhuria V; Kalra N; Soni R; Roy BG; Saluja D; Dwarakanath BS
PLoS One; 2015; 10(7):e0132089. PubMed ID: 26135741
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor immunity contributes to the radio-sensitization of ehrlich ascites tumor by the glycolytic inhibitor 2-deoxy-D-glucose in mice.
Farooque A; Singh N; Adhikari JS; Afrin F; Dwarakanath BS
PLoS One; 2014; 9(9):e108131. PubMed ID: 25248151
[TBL] [Abstract][Full Text] [Related]
7. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Holm B; Jensen PB; Sehested M
Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of radionuclide induced cytotoxicity by 2-deoxy-D-glucose in human tumor cell lines.
Shrivastava V; Mishra AK; Dwarakanath BS; Ravindranath T
J Cancer Res Ther; 2006; 2(2):57-64. PubMed ID: 17998676
[TBL] [Abstract][Full Text] [Related]
9. Polarization of macrophages towards M1 phenotype by a combination of 2-deoxy-d-glucose and radiation: Implications for tumor therapy.
Farooque A; Afrin F; Adhikari JS; Dwarakanath BS
Immunobiology; 2016 Feb; 221(2):269-81. PubMed ID: 26597503
[TBL] [Abstract][Full Text] [Related]
10. Optimization of tumour radiotherapy: Part V--Radiosensitization by 2-deoxy-D-glucose and DNA ligand Hoechst-33342 in a murine tumour.
Dwarakanath BS; Singh S; Jain V
Indian J Exp Biol; 1999 Sep; 37(9):865-70. PubMed ID: 10687280
[TBL] [Abstract][Full Text] [Related]
11. Glycolytic inhibitor, 2-deoxy-D-glucose, does not enhance radiation-induced apoptosis in mouse thymocytes and splenocytes in vitro.
Swamy RK; Manickam J; Adhikari JS; Dwarakanath BS
Indian J Exp Biol; 2005 Aug; 43(8):686-92. PubMed ID: 16121709
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells.
Varshney R; Dwarakanath B; Jain V
Int J Radiat Biol; 2005 May; 81(5):397-408. PubMed ID: 16076755
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines.
Dwarkanath BS; Zolzer F; Chandana S; Bauch T; Adhikari JS; Muller WU; Streffer C; Jain V
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):1051-61. PubMed ID: 11429233
[TBL] [Abstract][Full Text] [Related]
14. Optimization of tumor radiotherapy. Part VI: Modification of tumor glucose metabolism for increasing the bioavailability of 2-deoxy-D-glucose (2-DG) in a murine tumor model.
Sharma RK; Singh S; Degaonkar M; Raghunathan P; Maitra A; Jain V
Strahlenther Onkol; 2000 Mar; 176(3):135-43. PubMed ID: 10742835
[TBL] [Abstract][Full Text] [Related]
15. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
[TBL] [Abstract][Full Text] [Related]
16. Short-term exposure of multicellular tumor spheroids of a human glioma cell line to the glycolytic inhibitor 2-deoxy-D-glucose is more toxic than continuous exposure.
Khaitan D; Chandna S; Dwarakanath SB
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S67-73. PubMed ID: 20009299
[TBL] [Abstract][Full Text] [Related]
17. Experimental evaluation of the glucose antimetabolite, 2-deoxy-D-glucose (2-DG) as a possible adjuvant to radiotherapy of tumors: I. Kinetics of growth and survival of Ehrlich ascites tumor cells (EATC) in vitro and of growth of solid tumors after 2-DG and X-irradiation.
Purohit SC; Pohlit W
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):495-9. PubMed ID: 7107374
[No Abstract] [Full Text] [Related]
18. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions.
Maher JC; Krishan A; Lampidis TJ
Cancer Chemother Pharmacol; 2004 Feb; 53(2):116-22. PubMed ID: 14605866
[TBL] [Abstract][Full Text] [Related]
19. C-glycosyl Flavone from Urginea indica Inhibits Growth and Dissemination of Ehrlich Ascites Carcinoma Cells in Mice.
Bevara GB; Kumar ADN; Koteswramma K L; Badana AK; Kumari S; Yarla NS; Malla RR
Anticancer Agents Med Chem; 2017; 17(9):1256-1266. PubMed ID: 28044935
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
